To study the effects of 2 drugs, Cyclosporine 0.09% and Lifitegrast 5% in patients with dry eye disease

Comparison of efficacy and adverse effects of Cyclosporine 0.09% and Lifitegrast 5% in patients with dry eye disease- A Randomized Controlled Trial - Nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/09/094154

Enrollment

Registered

2025-09-03

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H119- Unspecified disorder of conjunctiva

Interventions

Intervention1: Lifitegrast 5%: Lifitegrast 5% is a LFA 1 antagonist used to treat dry eye disease Control Intervention1: Cyclosporine 0.09%: Cyclosporine 0.09% is calcineurin inhibitor immunosuppressa

Eligibility

Inclusion criteria

Inclusion criteria: Subjects included in this study are those who are above 18 years of age with clinical signs of dry eye disease and have been advised Cyclosporine 0.09% or Lifitegrast 5%

Exclusion criteria

Exclusion criteria: 1. Patients who have undergone any other forms of dry eye therapy like IPL, IRPL, Lipiflow 2. Patients not willing to participate in our study 3. Patients who are not willing to follow-up in our study

Design outcomes

Primary

Measure	Time frame
Improvement of symptoms of dry eye diseaseTimepoint: at base line 1 Month and 6 Months	—

Secondary

Measure	Time frame
Discontinued any drug due to adverse effectTimepoint: base line 1 month & 6 months	—

Countries

India

Contacts

Public ContactSarama S Raj

Chaithanya Eye Hospital And Research Institute

abkurian@gmail.com9495246083

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026